GLUT1 Antibody - #AF5462

>>买2送1 进行中>>
>>满百送 进行中>>
>>赠送JD卡 进行中>>
>>3倍积分 进行中>>
(16)   (18)  
产品: GLUT1 抗体
货号: AF5462
描述: Rabbit polyclonal antibody to GLUT1
应用: WB IHC IF/ICC
反应: Human, Mouse, Rat
预测: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
分子量: 45-60kDa; 54kD(Calculated).
蛋白号: P11166
RRID: AB_2837946

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat
预测:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(83%)
克隆:
Polyclonal
特异性:
GLUT1 Antibody detects endogenous levels of total GLUT1.
RRID:
AB_2837946
引用格式: Affinity Biosciences Cat# AF5462, RRID:AB_2837946.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Choreoathetosis/spasticity episodic (paroxysmal choreoathetosis/spasticity); CSE; DYT17; DYT18; DYT9; EIG12; erythrocyte/brain; Erythrocyte/hepatoma glucose transporter; facilitated glucose transporter member 1; Glucose transporter 1; Glucose transporter type 1; Glucose transporter type 1, erythrocyte/brain; GLUT; GLUT-1; GLUT1; GLUT1DS; GLUTB; GT1; GTG1; Gtg3; GTR1_HUMAN; HepG2 glucose transporter; HTLVR; Human T cell leukemia virus (I and II) receptor; MGC141895; MGC141896; PED; RATGTG1; Receptor for HTLV 1 and HTLV 2; SLC2A1; Solute carrier family 2 (facilitated glucose transporter), member 1; Solute carrier family 2; Solute carrier family 2, facilitated glucose transporter member 1;

抗原和靶标

免疫原:
Uniprot:

P11166(GTR1_HUMAN) >>Visit HPA database.

基因/基因ID:
SLC2A1(6513)
表达:
P11166 GTR1_HUMAN:

Detected in erythrocytes (at protein level). Expressed at variable levels in many human tissues.

描述:
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses.
序列:
MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWVHRYGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVSAVLMGFSKLGKSFEMLILGRFIIGVYCGLTTGFVPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIMGNKDLWPLLLSIIFIPALLQCIVLPFCPESPRFLLINRNEENRAKSVLKKLRGTADVTHDLQEMKEESRQMMREKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEKAGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRRTLHLIGLAGMAGCAILMTIALALLEQLPWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGMCFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQGGASQSDKTPEELFHPLGADSQV

种属预测

种属预测:

score>80的预测可信度较高，可尝试用于WB检测。*预测模型主要基于免疫原序列比对，结果仅作参考，不作为质保凭据。

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Chicken
83
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - P11166 作为底物

Site PTM Type Enzyme
M1 Acetylation
N45 N-Glycosylation
S118 Phosphorylation
S226 Phosphorylation
T234 Phosphorylation
T238 Phosphorylation
K245 Ubiquitination
T258 Phosphorylation
S465 O-Glycosylation
S465 Phosphorylation
S473 Phosphorylation
K477 Sumoylation
K477 Ubiquitination
T478 Phosphorylation
S490 Phosphorylation

研究背景

功能:

Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses. Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative transport of glucose into the brain.

翻译修饰:

Phosphorylation at Ser-226 by PKC promotes glucose uptake by increasing cell membrane localization.

细胞定位:

Cell membrane>Multi-pass membrane protein. Melanosome.
Note: Localizes primarily at the cell surface (PubMed:18245775, PubMed:19449892, PubMed:23219802, PubMed:25982116, PubMed:24847886). Identified by mass spectrometry in melanosome fractions from stage I to stage IV (PubMed:17081065).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Detected in erythrocytes (at protein level). Expressed at variable levels in many human tissues.

亚基结构:

Interacts with GIPC (via PDZ domain) (By similarity). Found in a complex with ADD2, DMTN and SLC2A1. Interacts (via C-terminus cytoplasmic region) with DMTN isoform 2. Interacts with SNX27; the interaction is required when endocytosed to prevent degradation in lysosomes and promote recycling to the plasma membrane. Interacts with STOM. Interacts with SGTA (via Gln-rich region) (By similarity).

蛋白家族:

Belongs to the major facilitator superfamily. Sugar transporter (TC 2.A.1.1) family. Glucose transporter subfamily.

研究领域

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Organismal Systems > Endocrine system > Insulin secretion.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

· Organismal Systems > Endocrine system > Glucagon signaling pathway.

文献引用

1). Bifunctional Cascading Nanozymes Based on Carbon Dots Promotes Photodynamic Therapy by Regulating Hypoxia and Glycolysis. ACS Nano, 2023 (PubMed: 37594768) [IF=17.1]
2). Chitosan biguanide induced mitochondrial inhibition to amplify the efficacy of oxygen-sensitive tumor therapies. Carbohydrate Polymers, 2022 (PubMed: 35989018) [IF=11.2]
3). Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3β signaling in pancreatic cancer. PHARMACOLOGICAL RESEARCH, 2021 (PubMed: 33992797) [IF=9.3]

Application: WB    Species: human    Sample: MIA PaCa-2 cells

Fig. 4. | Bruceine A induces cell growth inhibition and apoptosis via PFKFB4-mediated glycolysis in MIA PaCa-2 cells. (C) MIA PaCa-2 cells were treated with various concentrations of bruceine A for 24 h. Protein levels of GLUT1, HK2, PFKFB4, PFKM, PKM2, LDHA, and β-actin were detected. β-actin was served was as control. Results were expressed as means ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 versus control cultured with 0.1% DMSO by one-way ANOVA and post hoc tests.
4). Cisplatin conjugation with an exopolysaccharide extracted from Lactobacillus gasseri potentiates its efficacy and attenuates its toxicity. International Journal of Biological Macromolecules, 2023 (PubMed: 36354077) [IF=8.2]
5). Pimozide inhibits the growth of breast cancer cells by alleviating the Warburg effect through the P53 signaling pathway. BIOMEDICINE & PHARMACOTHERAPY, 2022 (PubMed: 35658233) [IF=7.5]

Application: WB    Species: Human    Sample: MCF-7 cells

Fig. 3. Pimozide inhibits PKM2 protein and mRNA in both MCF-7 and MDA-MB-231 cells in vitro. (A-B) Cells were treated with the indicated concentrations of Pimozide for 24 h, and the protein expression of glycolytic enzymes in MCF-7(A) and MDA-MB-231(B) cells were determined by Western blot analysis (left panel). Densitometry analysis was performed to assess the glycolytic enzymes protein expression (normalized to β-actin expression), PKM2 decreased significantly compared with untreated cells (right panel). (C-D) The mRNA expression of PKM2 in MCF-7(C) and MDA-MB-231(D) cells untreated or treated with Pimozide was determined by qRT-PCR. GAPDH was used as a control. Data represent mean ± SD from three biological replicates (*p < 0.05, **p < 0.01).
6). KHDRBS3 accelerates glycolysis and promotes malignancy of hepatocellular carcinoma via upregulating 14-3-3ζ. Cancer cell international, 2023 (PubMed: 37848941) [IF=5.8]

Application: WB    Species: Human    Sample: Huh7 cells

Fig. 7 KHDRBS3 binds to YWHAZ and upregulates its expression. (A) Relative mRNA levels of c-Myc, GLUT1, LDHA, YWHAZ, HOXB9, CRABP1 and DLL4 in stable KHDRBS3 knockdown or overexpressing Huh7 cells. (B) Protein levels of c-Myc, GLUT1, LDHA and 14-3-3ζ in infected Huh7 cells were evaluated by western blotting. (C) RIP assay was performed to detect the enrichment of c-Myc, GLUT1, LDHA and YWHAZ in the anti-KHDRBS3 IP group. (D) RNA pull-down assay determined the binding between KHDRBS3 and YWHAZ. Error bars represent standard deviation. **P 
7). Huanglian Jiedu Decoction enhances the stability of atherosclerotic plaques through SLC2A1-mediated efferocytosis. International immunopharmacology, 2024 (PubMed: 39116495) [IF=5.6]

Application: WB    Species: Mouse    Sample:

Fig. 10. HLJDD could anti-atherosclerosis through SLC2A1-mediated efferocytosis. A: Representative image of SLC2A1 expression in the aortic root of mice (scale bar: 200 µm). B: Quantification of expression level of SLC2A1 in aortic roots. C: Western blotting for SLC2A1 in BMDMs with the intervention of HLJDD. D: Densitometric analysis of SLC2A1 in aorta (n = 3). E: Western blotting for SLC2A1 in BMDMs with the intervention of STF31 (an inhibitor of SLC2A1). F: Western blotting for SLC2A1 in BMDMs with the intervention of HLJDD and STF31. G: Densitometric analysis of SLC2A1 in BMDMs (n = 3). H: Relatively mRNA expression levels of TYRO3, AXL, and MERTK in BMDMs (n = 5). I: Western blotting for TYRO3, AXL, and MERTK in BMDMs. J: Densitometric analysis of TYRO3, AXL, and MERTK in BMDMs (n = 3). K: The co-localization of BMDMs and apoptotic VSMCs with the intervention of HLJDD and STF31 (scale bar: 100 µm). L: The statistical chart of efferocytosis index (n = 3). *P＜0.05, **P＜0.01, ***P＜0.001.

Application: IHC    Species: Mouse    Sample:

Fig. 10. HLJDD could anti-atherosclerosis through SLC2A1-mediated efferocytosis. A: Representative image of SLC2A1 expression in the aortic root of mice (scale bar: 200 µm). B: Quantification of expression level of SLC2A1 in aortic roots. C: Western blotting for SLC2A1 in BMDMs with the intervention of HLJDD. D: Densitometric analysis of SLC2A1 in aorta (n = 3). E: Western blotting for SLC2A1 in BMDMs with the intervention of STF31 (an inhibitor of SLC2A1). F: Western blotting for SLC2A1 in BMDMs with the intervention of HLJDD and STF31. G: Densitometric analysis of SLC2A1 in BMDMs (n = 3). H: Relatively mRNA expression levels of TYRO3, AXL, and MERTK in BMDMs (n = 5). I: Western blotting for TYRO3, AXL, and MERTK in BMDMs. J: Densitometric analysis of TYRO3, AXL, and MERTK in BMDMs (n = 3). K: The co-localization of BMDMs and apoptotic VSMCs with the intervention of HLJDD and STF31 (scale bar: 100 µm). L: The statistical chart of efferocytosis index (n = 3). *P＜0.05, **P＜0.01, ***P＜0.001.
8). Inhibition of microRNA-327 ameliorates ischemia/reperfusion injury-induced cardiomyocytes apoptosis through targeting apoptosis repressor with caspase recruitment domain. JOURNAL OF CELLULAR PHYSIOLOGY, 2020 (PubMed: 31587299) [IF=5.6]
9). Silencing of ANGPTL8 Alleviates Insulin Resistance in Trophoblast Cells. Frontiers in Endocrinology, 2021 (PubMed: 34163433) [IF=5.2]
10). Icaritin activates p53 and inhibits aerobic glycolysis in liver cancer cells. Chemico-biological interactions, 2024 (PubMed: 38431053) [IF=5.1]
加载更多

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.